LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio
Executive Chair Mark Crotty to continue guiding long-term strategic direction PERTH, Australia, July 15, 2026 /PRNewswire/ -- LumaCina, a global supplier and marketer of sterile injectable pharmaceutical products and a Bridgewest Group portfolio company, announced the appointment of Gary Bird as Chief Executive Officer. Gary Bird, Chief Executive Officer, LumaCina Bird was appointed by Executive...
GEM and Senhwa Biosciences have formally executed a Share Purchase Agreement for up to NT$500 million
TAIPEI and SAN DIEGO, July 15, 2026 /PRNewswire/ -- GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc. (TPEx: 6492), under which GEM has committed up to NT$500 million (approximately US$15.5 million) to purchase shares in the...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX:...
Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the Phase III clinical trial evaluating its core product zemprocitinib capsules for the treatment of active ankylosing spondylitis...
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a positive OS trend compared with pembrolizumab plus pemetrexed and platinum-based chemotherapy. Focusing on the...
ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process
NEWARK, Del., July 15, 2026 /PRNewswire/ -- Recently, ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for its GMP-grade Human IL-15 protein. This recognition further validates ACROBiosystems' quality system and serves as an authoritative endorsement of its compliance capabilities and expertise...
NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists’ Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act
WASHINGTON, July 14, 2026 /PRNewswire/ -- On July 14, 2026, the U.S. Fish and Wildlife Service ("USFWS") for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals ("PETA") and other activist groups to list long-tailed macaque ("LTM") monkeys (Macaca fascicularis) under the U.S. Endangered Species Act ("ESA"). NABR-Logo-1...
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 proof-of-concept trial for cardiovascular risk reduction. The QUELL-CV trial is designed to inform optimal dose selection in Phase 3 and BGE-102's path...
Rayence Launches ‘SHINE,’ a Next-Generation X-ray Image Processing Technology for Low Dose Imaging
- Development of next-generation denoising image processing technology 'SHINE' completed; full-scale commercialization now underway - Development of 'Dynamic SHINE,' optimized for real-time C-arm fluoroscopy, also completed - SHINE is expected to help global X-ray equipment manufacturers accelerate system development HWASEONG, South Korea, July 14, 2026 /PRNewswire/ -- As the global healthcare...
Samyang Corporation Unveils New Crystalline Dietary Fiber Brand ‘Fibernova’ at IFT 2026
Participates in IFT 2026, the international food technology expo held in Chicago, U.S., from July 13 to 15 Names its crystalline dietary fiber brand "Fibernova," signifying an innovative next-generation dietary fiber ingredient Presents metabolic research findings on Samyang Corporation's specialty food ingredients…showcases their potential applications in food product development to global customers SEOUL, South Korea, July...
